Kokacya, Mehmet HanifiInanir, SemaCopoglu, Umit SertanDokuyucu, RecepErbas, Oytun2024-09-182024-09-1820150002-96291538-2990https://doi.org/10.1097/MAJ.0000000000000531https://hdl.handle.net/20.500.12483/13434Background: In humans, omega-3 fatty acids are necessary for cell membranes, brain function and nerve transmission continuation. When animals are exposed to a new environment-or as a result of an apomorphine application that creates an agonistic effect on D1 and D2 receptors-they display behavioral reactions like rearing and stereotypy. This study aims to reveal the possible antipsychotic and oxidative effects of omega-3 fatty acids by comparing with chlorpromazine, a conventional antipsychotic drug, through evaluating the novelty-induced rearing and apomorphine-induced stereotypic behaviors, as well as malondialdehyde and glutathione levels in rats. Methods: Twenty-eight, adult, male, Wistar rats were used in the study. Briefly, 4 groups of rats (n = 7) were administered docosahexaenoic acid (DHA) + eicosapentaenoic acid (EPA) (300 mg/kg; DHA: 120 mg/kg + EPA: 180 mg/kg intraperitoneally [IP]), DHA + EPA (150 mg/kg; DHA: 60 mg/kg + EPA: 90 mg/kg IP), chlorpromazine (1 mg/kg, IP) and isotonic saline (1 mL/kg, IP). One hour later, apomorphine (2 mg/kg, subcutaneously) was administered to each rat. After the apomorphine administration, rats were observed for stereotypic behavior. Results: This study shows that omega-3 fatty acids, similar to antipsychotics, reversed the psychotic like effects, increase of oxidants and decrease of antioxidants that are composed experimentally in rats. Conclusions: The application of omega-3 fatty acids has antipsychotic effects and causes an oxidative imbalance. This study adds new evidence to the current literature regarding the possible antipsychotic effects of omega-3 fatty acids.eninfo:eu-repo/semantics/closedAccessPlacebo-Controlled-TrialEthyl-Eicosapentaenoic AcidOxidative StressFatty-AcidsAtypical AntipsychoticsSchizophrenic-PatientsDopamine-ReceptorsBipolar DisorderSupplementationPreventionArticle350321221710.1097/MAJ.0000000000000531262009502-s2.0-84941133103Q1WOS:000360817700010Q2